634 related articles for article (PubMed ID: 15208660)
1. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
[TBL] [Abstract][Full Text] [Related]
2. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
3. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells.
Gong B; Almasan A
Cancer Res; 2000 Oct; 60(20):5754-60. PubMed ID: 11059770
[TBL] [Abstract][Full Text] [Related]
4. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
[TBL] [Abstract][Full Text] [Related]
5. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells.
Kim YH; Park JW; Lee JY; Kwon TK
Carcinogenesis; 2004 Oct; 25(10):1813-20. PubMed ID: 15142888
[TBL] [Abstract][Full Text] [Related]
6. Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis.
Yoshida T; Shiraishi T; Horinaka M; Nakata S; Yasuda T; Goda AE; Wakada M; Mizutani Y; Miki T; Nishikawa A; Sakai T
Cancer Sci; 2007 Sep; 98(9):1417-23. PubMed ID: 17645780
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
8. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells.
Horinaka M; Yoshida T; Shiraishi T; Nakata S; Wakada M; Nakanishi R; Nishino H; Sakai T
Biochem Biophys Res Commun; 2005 Aug; 333(3):833-8. PubMed ID: 15963948
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K
Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK; VanOosten RL; Griffith TS
Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
13. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
14. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
15. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
[TBL] [Abstract][Full Text] [Related]
17. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway.
He Q; Lee DI; Rong R; Yu M; Luo X; Klein M; El-Deiry WS; Huang Y; Hussain A; Sheikh MS
Oncogene; 2002 Apr; 21(17):2623-33. PubMed ID: 11965535
[TBL] [Abstract][Full Text] [Related]
18. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells.
Horinaka M; Yoshida T; Shiraishi T; Nakata S; Wakada M; Nakanishi R; Nishino H; Matsui H; Sakai T
Oncogene; 2005 Nov; 24(48):7180-9. PubMed ID: 16007131
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Singh TR; Shankar S; Srivastava RK
Oncogene; 2005 Jul; 24(29):4609-23. PubMed ID: 15897906
[TBL] [Abstract][Full Text] [Related]
20. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]